NCT00615524WithdrawnPhase 2
A Randomized, Double-blind, Placebo-controlled, Multicenter Phase II Study to Compare the Efficacy and Tolerability of Pazopanib Administered in Combination With Exemestane Versus Exemestane Plus Placebo in Postmenopausal Subjects With Advanced or Metastatic Hormone Receptor Positive Breast Cancer
Conditions
Drugs
Trial Snapshot
- Phase
- Phase 2
- Status
- Withdrawn
- Sponsor
- GlaxoSmithKline
- Locations
- 2
- Primary Endpoint
- Progression free survival
Study Overview
Brief Summary
This study is being conducted to compare the efficacy and safety of exemestane alone or in combination with pazopanib in postmenopausal women who have hormone receptor positive breast cancer and have failed therapy with tamoxifen, anastrazole or letrozole.
Study Design
- Study Type
- Interventional
- Allocation
- Randomized
- Intervention Model
- Parallel
- Primary Purpose
- Treatment
- Masking
- Double
Eligibility Criteria
- Ages
- 18 Years to — (Adult, Older Adult)
- Sex
- Female
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- •Subjects must have measurable disease OR must be evaluable for disease progression
- •Age >/= 18 years.
- •Postmenopausal women
- •Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0 or
- •Histologically or cytologically confirmed ER and/or PgR positive carcinoma of the breast with unresectable, locally advanced and/or metastatic disease
- •Subjects must have received prior hormonal therapy for the treatment of breast cancer (anastrozole, letrozole, or tamoxifen)
- •Adequate hematologic, hepatic, and renal function
Exclusion Criteria
- •Prior use of exemestane or pazopanib
- •Premenopausal women
- •Any ongoing toxicity from prior anti-cancer therapy that is >Grade 1 and/or that is progressing in severity.
- •Prior therapy with a VEGF inhibitor.
- •Use of an investigational agent, including an investigational anti-cancer agent, within 28 days or 5 half-lives, whichever is longer, prior to the first dose of investigational product.
- •Evidence of recurrence or active disease from prior malignancy.
- •Clinically significant gastrointestinal abnormalities that may increase the risk for GI bleeding or affect the absorption of the investigational product(s).
- •Presence of uncontrolled infection.
- •History of any major cardiovascular conditions within the past 6 months:
- •Poorly controlled hypertension
- •History of cerebrovascular accident, pulmonary embolism or untreated deep venous thrombosis (DVT) within the past 6 months.
- •Prior major surgery or trauma within 28 days prior to first dose of investigational product and/or presence of any non-healing wound, fracture, or ulcer
- •Evidence of active bleeding or bleeding tendency.
Outcomes
Primary Outcomes
Progression free survival
Secondary Outcomes
- Safety and tolerability Overall response rate (complete and partial responses) in subjects with measurable disease Overall survival Change in health-related quality of life (HRQL) relative to baseline Biomarkers
Investigators
Study Sites (2)
Loading locations...
Similar Trials
Terminated
Phase 3
TAF/FTC for Pre-exposure Prophylaxis of COVID-19 in Healthcare Workers (CoviPrep Study)Healthcare WorkersCOVID-19SARS-CoV 2NCT04405271Hospital Italiano de Buenos Aires1,378
Completed
Phase 2
Exploratory Study of MT-8554 in Subjects With Painful Diabetic Peripheral NeuropathyPainful Diabetic Peripheral NeuropathyNCT05123196Tanabe Pharma Corporation156
Completed
Phase 1
Study to Evaluate Erlotinib With or Without SNDX-275 (Entinostat) in the Treatment of Patients With Advanced NSCLCNon-Small-Cell Lung CarcinomaCarcinoma, Non-Small Cell LungNCT00602030Syndax Pharmaceuticals141
Completed
Phase 2
Safety and Efficacy of Exemestane Plus Dasatinib Versus Placebo for Advanced ER+ Breast CancerBreast CancerNCT00767520Bristol-Myers Squibb155
Completed
Phase 3
Epinastine + Pseudoephedrine SR (Slow Release) Versus Epinastine Alone in Patients With Perennial Allergic RhinitisRhinitis, Allergic, PerennialNCT02182518Boehringer Ingelheim101